PEG-glutaminase/Diazo-oxo-L-norleucine

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePEG-glutaminase/Diazo-oxo-L-norleucine
Drug Alias NameGlutaDON
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Diazo-oxo-L-norleucine
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNew Medical Enzymes Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNew Medical Enzymes Ag
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A